Therapeutics News

BOSTON – Once daily latanoprostene bunod 0.024%, taken in the evening, reduced IOP in subjects with open angle glaucoma or ocular hypertension significantly, compared to the IOP-lowering capability of timolol 0.5% twice daily, according to a poster presented by Murray Fingeret, OD, and Jason L. Vittitow, PhD, here at Optometry’s Meeting.

BOSTON – Optometrists earned more than $18 million in 2014 as a result of financial relationships with the medical industry, according to a study presented here at Optometry’s Meeting.

The FDA announced today that it approved lifitegrast for treating the signs and symptoms of dry eye disease in adults on July 11.

BOSTON – PARx helps physicians through the process when a drug they prescribe requires prior authorization from the insurer.

BOSTON – Steven Ferrucci, OD, FAAO, discusses the systemic aspects of diabetes here at Optometry’s Meeting. Ferrucci is chief of optometry at the Sepulveda VA and a professor at the Southern California College of Optometry.

Researchers found that daily evening treatments of latanoprostene bunod were noninferior to timolol twice daily for 3 months and resulted in significantly greater IOP lowering in subjects with open angle glaucoma or ocular hypertension, according to a study in the American Journal of Ophthalmology. 

Short-term statin use was found to be associated with a reduced incidence of glaucoma, but no association was found with IOP, according to a study in Investigative Ophthalmology & Visual Science.

A new modular device may help increase compliance rates among patients taking ocular medications.

The use of minimally invasive glaucoma surgery has grown in the U.S. Here are three reasons why our old standard glaucoma drops may one day be relegated to second-line therapy:

Twice-daily treatment with one drop of EV06 ophthalmic solution 1.5% improved distance-corrected near vision acuity efficacy measures when compared to placebo in a phase 1/2 study.